sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Granted Approval for Phase II Trial of NV-387 for MPox Treatment
NanoViricides, Inc. has received approval from the DRC's regulatory agency ACOREP to commence a Phase II clinical trial of NV-387 for treating MPox. This trial aims to assess the safety and efficacy of NV-387 against hMPXV infections. The approval marks a key milestone in the regulatory journey of NV-387.
No effective treatments for hMPXV infections currently exist. Tecovirimat, another potential treatment, showed no superiority over placebo in trials. NV-387, however, promises a broad-spectrum antiviral solution, targeting a vast range of human pathogenic viruses via biomimicry.
NV-387's broad efficacy was demonstrated across various viruses, including influenza and coronavirus, where it outperformed existing drugs. With community spread of MPox Clade I emerging in the US, the development of NV-387 could be significant in combating viral threats globally.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.